From GlobeNewswire: 2025-06-04 08:45:00

Moleculin Biotech, Inc. announced positive results from its Phase 1B/2 trial of Annamycin for STS lung mets. The Clinical Benefit Rate was 59.4%, with improved PFS and OS. The potential market opportunity for addressing new STS incidents is estimated at $2.6B by 2030. An on-demand webcast discussing the data will be available on June 5th. Annamycin has FDA Fast Track Status and Orphan Drug Designation for treating AML and STS. The study design for Annamycin involves monitoring tumor response every 6 weeks. Moleculin is focused on developing treatments for hard-to-treat tumors and viruses.



Read more at GlobeNewswire: Moleculin Reports Positive Topline Efficacy Results from